文献速递神经肿瘤

视觉与半定量11C-甲硫氨酸PET:初诊未治疗胶质瘤生存的独立预后因素

Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.
PubMed 文献 · Neuro Oncol · 2018-01-01

160例初诊未治疗胶质瘤患者治疗前接受MET PET,视觉评估与T/N比值半定量分析显示,氨基酸高摄取者平均生存期显著短于视觉阴性者(7.2 vs 8.6年,P=0.024),T/N阈值2.1和3.5与生存显著相关(10.3 vs 7 vs 4.3年,P<0.001),半定量MET PET为独立预后参数。

要点

  • MET PET视觉阳性胶质瘤患者平均生存期显著短于视觉阴性者(7.2 vs 8.6年,P=0.024)。
  • T/N比值阈值2.1和3.5与生存显著相关(10.3 vs 7 vs 4.3年,P<0.001)。
  • 以中位T/N比值2.4为界,平均生存期10.2±0.8年 vs 5.5±0.6年,独立于组织病理学(P<0.01)。

核心结论

  • 该回顾性分析表明MET PET可作为初诊未治疗胶质瘤患者生存的预后参数。

研究设计与样本

  • 回顾性分析纳入160例胶质瘤患者(89男,71女;平均年龄45岁,范围18-84岁),在任何治疗前接受MET PET。
  • PET扫描通过受试者工作特征分析选择的肿瘤/背景(T/N)比值阈值进行视觉和半定量评估,并进行IDH1-R132H免疫组化。
  • 生存分析采用Kaplan-Meier估计和Cox比例风险模型。

主要发现

  • 氨基酸高摄取胶质瘤患者(n=137)平均生存期显著短于视觉阴性肿瘤患者(n=33)(7.2 vs 8.6年;P=0.024)。
  • T/N比值阈值2.1和3.5与生存显著相关(10.3 vs 7 vs 4.3年;P<0.001)。
  • 以中位T/N比值2.4为 cutoff,平均生存期差异显著,独立于组织病理学(P<0.01;平均生存期:10.2±0.8年 vs 5.5±0.6年)。
  • 在142例具有IDH1-R132H状态的胶质瘤患者亚组中,MET T/N比值在IDH1-R132H野生型星形细胞瘤和胶质母细胞瘤中显示显著预后影响(P=0.001)。
  • 多因素检验显示半定量MET PET为初诊未治疗胶质瘤患者的独立预后参数,无IDH1-R132H特征者P=0.031,有IDH1-R132H特征者P=0.024(比值比1.57)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few data exist regarding the prognostic value of L-[S-methyl-11C]methionine (MET) PET for treatment-naïve gliomas. METHODS: A total of 160 glioma patients (89 men, 71 women; mean age: 45, range 18-84 y) underwent a MET PET prior to any therapy. The PET scans were evaluated visually and semiquantitatively by tumor-to-background (T/N) ratio thresholds chosen by analysis of receiver operating characteristics. Additionally, isocitrate dehydrogenase 1-R132H (IDH1-R132H) immunohistochemistry was performed. Survival analysis was done using Kaplan-Meier estimates and the Cox proportional hazards model. RESULTS: Significantly shorter mean survival times (7.2 vs 8.6 y; P = 0.024) were seen in patients with amino acid avid gliomas (n = 137) compared with visually negative tumors (n = 33) in MET PET. T/N ratio thresholds of 2.1 and 3.5 were significantly associated with survival (10.3 vs 7 vs 4.3 y; P < 0.001). Mean survival differed significantly using the median T/N ratio of 2.4 as cutoff, independent of histopathology (P < 0.01; mean survival: 10.2 ± 0.8 y vs 5.5 ± 0.6 y). In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001). Additionally, multivariate testing revealed semiquantitative MET PET as an independent prognostic parameter for treatment-naïve glioma patients without (P = 0.031) and with IDH1-R132H characterization of gliomas (P = 0.024; odds ratio 1.57). CONCLUSION: This retrospective analysis demonstrates the value of MET PET as a prognostic parameter on survival in treatment-naïve glioma patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Poetsch N, Woehrer A, Gesperger J, et al. Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas. Neuro Oncol. 2018. PMID: 29016947. doi:10.1093/neuonc/nox177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。